title: Invasive reperfusion study. II. Multicentre European randomized trial of anistreplase vs streptokinase in acute myocardial infarction.
abstract: IRS II (Invasive reperfusion study II) was a multicentre randomized trial comparing the efficacy of a 2-5-min 30 U anistreplase intravenous injection with a 1,500,000 U 60-min streptokinase (SK) intravenous infusion in acute myocardial infarction. 116 patients were randomized within 6 h of onset of symptoms. Early coronary patency was assessable in 107 patients by coronary angiogram performed 102 min after thrombolytic treatment (range: 30-297 min) in the anistreplase group and 93 min (range: 22-330 min) in the SK group. The early coronary patency rate was significantly higher in the anistreplase group than in the SK group: respectively, 70% (38/54) and 51% (27/53), P less than 0.05). Fifty patients had assessable coronary angiograms at 90 min and 24 h. The 24-h patency rate was 92.3% (24/26) in the anistreplase group vs 87.5% (21/24) in the SK group. No early reocclusion occurred in the anistreplase group vs 15.4% (2/13) in the SK group (NS). Fibrinogen fell to 13.2 +/- 19.8% on anistreplase vs 9.4 +/- 10.3% on SK (NS). Bleeding complications occurred in 12% (7/58) of treated patients in the anistreplase group vs 20.7% (13/58) in the SK group (NS). Two cerebrovascular accidents occurred after thrombolytic treatment with anistreplase (3.4%) vs one after SK (1.7%) (NS). Thus, anistreplase is more effective than intravenous SK and easier to administer.
authors.affiliation: Cardiology Department, University Hospital Trousseau, Tours, France.
authors.forename: G
authors.initials: G
authors.lastname: Pacouret
authors.forename: B
authors.initials: B
authors.lastname: Charbonnier
authors.forename: N D
authors.initials: ND
authors.lastname: Curien
authors.forename: J P
authors.initials: JP
authors.lastname: Monassier
authors.forename: A
authors.initials: A
authors.lastname: Cribier
authors.forename: P
authors.initials: P
authors.lastname: Materne
authors.forename: M L
authors.initials: ML
authors.lastname: Brochier
authors.forename: R
authors.initials: R
authors.lastname: Letac
authors.forename: M
authors.initials: M
authors.lastname: Hanssen
authors.forename: A
authors.initials: A
authors.lastname: Sacrez
mesh_terms: D000328:Adult; D000368:Aged; D016255:Anistreplase / Q000008:administration & dosage*; D017023:Coronary Angiography; D003326:Coronary Circulation / Q000187:drug effects*; D005260:Female; D005500:Follow-Up Studies; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007260:Infusion Pumps; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality / Q000628:therapy*; D012008:Recurrence; D013300:Streptokinase / Q000008:administration & dosage*; D015996:Survival Rate
chemical_list: D016255:Anistreplase; D013300:Streptokinase